A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...

Circadian rhythms are endogenous oscillations widely present in living organisms, typically following approximately 24-hour ...

DNA sequencing technology makes it possible to explore the genome to learn how humans adapted to live in a wide range of ...

A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...

Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of ...

Andean highlanders adapt to thin air through epigenetic gene tuning, revealing a flexible, long-term path to altitude survival.

Researchers at the Cornell University College of Veterinary Medicine (CVM) are a step closer to finding the fountain of youth ...

Vaderis Therapeutics today announced that data from its randomized, double-blind, placebo-controlled, multi-center ...

DNA sequencing technology makes it possible to explore the genome to learn how humans adapted to live in a wide range of environments. Research has ...

This peer-reviewed publication marks an important milestone following initial release of study information in August 2024 (see "Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT"). The ...